Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats
详细信息 查看全文
- 作者：Klaudia Kwiatkowskia ; Anna Piotrowskaa ; Ewelina Rojewskaa ; Wioletta Makucha ; Agnieszka Jurgaa ; Joanna Slusarczykb ; Ewa Trojanb ; Agnieszka Basta-Kaimb ; Joanna Mikaa ; joamika@if-pan.krakow.pl" class="auth_mail" title="E-mail the corresponding author
- 关键词：ANOVA ; analysis of variance ; B ; buprenorphine ; CCI ; chronic constriction injury ; CCL ; CC chemokine ligands ; CCR5 ; CC chemokine receptor 5 ; C1q ; complement component C1q ; DMSO ; dimethyl sulfoxide ; DRG ; dorsal root ganglia ; GFAP ; glial fibrillary acidic protein ; GPCR ; G protein-coupled receptors ; HIV ; human immunodeficiency virus ; HPRT ; hypoxanthine-guanine phosphoribosyl transferase ; IASP ; International Association for the Study of Pain ; Iba-1 ; ionized calcium-binding adapter molecule 1 ; i.p ; int
- 刊名：Progress in Neuropsychopharmacology & Biological Psychiatry
- 出版年：2016
- 出版时间：4 January 2016
- 年：2016
- 卷：64
- 期：Complete
- 页码：68-78
- 全文大小：1217 K
文摘
- •
Maraviroc attenuated neuropathic pain symptoms and enhanced opioid analgesia.
- •
Maraviroc decreased protein level of Iba-1 and GFAP.
- •
Maraviroc diminished CCI-induced up-regulation of CCR5 in the spinal cord and DRG.
- •
Maraviroc suppressed CCI-induced spinal up-regulation of CCL3, CCL4 and CCL5.
- •
CCL3, CCL4, CCL5 and CCL7 up-regulation were observed in glial LPS-treated cells.